-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhongguancun (000931.SZ) subsidiary company's application for permission to list Dortinolide was accepted

Zhitongcaijing·08/05/2026 10:41:17
Listen to the news

Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for dortinolide tablets (specifications: 1 mg, 2 mg) was accepted. Dotinolide tablets are suitable for patients with gout with hyperuricemia. They can selectively inhibit URAT1, a transporter of uric acid reabsorption in the kidneys, promote the excretion of uric acid filtered by glomeruli through urine, and reduce blood uric acid levels.